Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction

被引:80
作者
Matsui, Shigeru [2 ]
Ishii, Junnichi [1 ]
Kitagawa, Fumihiko [3 ]
Kuno, Atsuhiro [3 ]
Hattori, Kousuke [4 ]
Ishikawa, Makoto [4 ]
Okumura, Masanori [4 ]
Kan, Shino [4 ]
Nakano, Tadashi [4 ]
Naruse, Hiroyuki [4 ]
Tanaka, Ikuko [1 ]
Nomura, Masanori [4 ]
Hishida, Hitoshi [4 ]
Ozaki, Yukio [4 ]
机构
[1] Fujita Hlth Univ, Sch Med, Dept Joint Res, Lab Clin Med, Toyoake, Aichi 4701192, Japan
[2] Fujita Hlth Univ, Grad Sch Hlth Sci, Div Crit Care, Toyoake, Aichi 4701192, Japan
[3] Fujita Hlth Univ Hosp, Lab Clin Med, Dept Joint Res, Toyoake, Aichi, Japan
[4] Fujita Hlth Univ, Sch Med, Dept Internal Med, Toyoake, Aichi 4701192, Japan
关键词
Pentraxin; 3; Prognosis; Unstable angina; Non-ST-segment elevation myocardial infarction; CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; LONG PENTRAXIN; NATRIURETIC PEPTIDE; PTX3; INFLAMMATION; STRATEGIES; MARKER; CRP;
D O I
10.1016/j.atherosclerosis.2009.10.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We prospectively investigated the prognostic value of pentraxin 3 (PTX3) in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). Background: PTX3 may be a useful marker for localized vascular inflammation and damage to the cardiovascular system. Recent studies have shown that plasma PTX3 is elevated in patients with UA/NSTEMI; however, its prognostic value in UA/NSTEMI remains unclear. Methods: PTX3, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac troponin I were measured on admission in 204 consecutive patients (mean age of 69 years; 144 males) hospitalized for UA/NSTEMI within 24 h (mean of 7.5 h) after the onset of chest symptoms. A cardiac event, which was defined as cardiac death, rehospitalization for acute coronary syndrome (ACS), or rehospitalization for worsening heart failure, was monitored for 6 months after admission. Results: A total of 26 (13%) cardiac events occurred during the 6-month follow-up period. In a stepwise Cox regression analysis including 18 well-known clinical and biochemical predictors of ACS outcome, both PTX3 (relative risk 3.86 per 10-fold increment, P = 0.01) and NT-proBNP (relative risk 2.16 per 10-fold increment, P = 0.02), but not hsCRP, were independently associated with the 6-month cardiac event. The cardiac event rate was higher in patients with increased PTX3 (>= 3.1 ng/mL of median value) than those without (20% vs. 5.8%, P = 0.003). A Kaplan-Meier analysis revealed that patients with increased PTX3 had a higher risk for cardiac events than those without (P = 0.002). Conclusion: PTX3 and NT-proBNP may be potent and independent predictors for 6-month cardiac events in patients hospitalized for UA/NSTEMI within 24 h after the onset. Measurement of plasma PTX3 may substantially improve the early risk strati. cation of patients with UA/NSTEMI. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:220 / 225
页数:6
相关论文
共 22 条
[1]   CRP after 2004 [J].
Agrawal, A .
MOLECULAR IMMUNOLOGY, 2005, 42 (08) :927-930
[2]   Characterization of the promoter for the human long pentraxin PTX3 - Role of NF-kappa B in tumor necrosis factor-alpha and interleukin-1 beta regulation [J].
Basile, A ;
Sica, A ;
dAniello, E ;
Breviario, F ;
Garrido, G ;
Castellano, M ;
Mantovani, A ;
Introna, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (13) :8172-8178
[3]   THE ACUTE-PHASE RESPONSE [J].
BAUMANN, H ;
GAULDIE, J .
IMMUNOLOGY TODAY, 1994, 15 (02) :74-80
[4]   Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].
Cannon, CP ;
Weintraub, WS ;
Demopoulos, LA ;
Vicari, R ;
Frey, MJ ;
Lakkis, N ;
Neumann, FJ ;
Robertson, DH ;
DeLucca, PT ;
DiBattiste, PM ;
Gibson, CM ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887
[5]   Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility [J].
Garlanda, C ;
Bottazzi, B ;
Bastone, A ;
Mantovani, A .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :337-366
[6]   Establishment of a high sensitivity plasma assay for human Pentraxin3 as a marker for unstable angina pectoris [J].
Inoue, Kenji ;
Sugiyama, Akira ;
Reid, Patrick C. ;
Ito, Yukio ;
Miyauchi, Katsumi ;
Mukai, Sei ;
Sagara, Mina ;
Miyamoto, Kyoko ;
Satoh, Hirokazu ;
Kohno, Isao ;
Kurata, Takeshi ;
Ota, Hiroshi ;
Mantovani, Alberto ;
Hamakubo, Takao ;
Daida, Hiroyuki ;
Kodama, Tatsuhiko .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (01) :161-167
[7]   N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease -: A Global Utilization of Strategies to Open occluded arteries (GUSTO)-IV substudy [J].
James, SK ;
Lindahl, B ;
Siegbahn, A ;
Stridsberg, M ;
Venge, P ;
Armstrong, P ;
Barnathan, ES ;
Califf, R ;
Topol, EJ ;
Simoons, ML ;
Wallentin, L .
CIRCULATION, 2003, 108 (03) :275-281
[8]   Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause Death The Cardiovascular Health Study [J].
Jenny, Nancy Swords ;
Arnold, Alice M. ;
Kuller, Lewis H. ;
Tracy, Russell P. ;
Psaty, Bruce M. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (04) :594-599
[9]   Prognostic value of pentraxin 3 in patients with chronic heart failure [J].
Kotooka, Norihiko ;
Inoue, Teruo ;
Aoki, Shigehisa ;
Anan, Mayumi ;
Komoda, Hiroshi ;
Node, Koichi .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 130 (01) :19-22
[10]   Protective molecules - C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: Prevalence and clinical significance in autoimmunity [J].
Kravitz, MS ;
Pitashny, M ;
Shoenfeld, Y .
JOURNAL OF CLINICAL IMMUNOLOGY, 2005, 25 (06) :582-591